Latent Labs has launched LatentX, a web-based AI model for protein design, six months after securing $50 million in funding. The model aims to democratise access to advanced protein engineering for researchers and pharmaceutical companies.
LatentX has demonstrated state-of-the-art performance in lab tests, with high viability rates in designed proteins. Unlike AlphaFold's structure prediction, LatentX generates novel biological entities, potentially accelerating drug discovery and reducing costs for previously untreatable conditions. The company's licensing model prioritises accessibility, offering free access while planning paid advanced features to sustain innovation.
Latent Labs' commitment to accessibility is a key aspect of its approach, offering a web-based model that can be accessed by a wide range of users. This empowers both academic researchers and large pharmaceutical companies to design novel proteins directly from their web browsers.
